Key Highlights
- Skye Bioscience will merge with Redx Pharma to establish Fibrx Therapeutics, a new Nasdaq-listed entity.
- The combined company will be dedicated to fibrosis and steered by Redx leadership.
- The firm will prioritize RXC008, a GI-restricted pan-ROCK inhibitor with Fast Track Designation for fibrostenotic Crohn's disease.
- The Merger is supported by $125 million in secured funding intended to extend the cash runway into 2029.
Skye Bioscience, Inc. (NASDAQ: SKYE) announced it will merge with Redx Pharma to establish Fibrx Therapeutics, a new Nasdaq-listed entity dedicated to fibrosis and steered by Redx leadership.
What Happened
The combined firm will prioritize RXC008, a GI-restricted pan-ROCK inhibitor with Fast Track designation for fibrostenotic Crohn's disease, supported by $125 million in secured funding intended to extend the cash runway into 2029 and through Phase 2 results anticipated in the second half of 2028.
Market Reaction
The disclosed information does not include stock price or trading data for Skye Bioscience following the merger announcement.
Outlook
Phase 2 results for RXC008 in fibrostenotic Crohn's disease, anticipated in the second half of 2028, represent the next major disclosed milestone for the combined Fibrx Therapeutics entity.
FAQs
Q: What new entity will result from the Skye Bioscience and Redx Pharma merger?
A: Fibrx Therapeutics, a new Nasdaq-listed company dedicated to fibrosis and steered by Redx leadership.
Q: What is the combined company's lead program?
A: RXC008, a GI-restricted pan-ROCK inhibitor with Fast Track designation for fibrostenotic Crohn's disease.
Q: How much funding supports the merger, and how far does it extend the cash runway?
A: $125 million in secured funding, intended to extend the cash runway into 2029 and through Phase 2 results anticipated in the second half of 2028.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.